

NALBAIN

NEW

DEAR HEALTHCARE PROFESSIONAL,

Arya Pharma is honoured to announce the launch of Nalbain solution for injection in South Africa!

NALBAIN INJECTION is indicated in adults for the **management of pain severe** enough to require an opioid analgesic and for which alternative treatments are inadequate.

As a supplement to balanced anaesthesia, for:

- Pre-operative and post-operative analgesia.
- Obstetrical analgesia during labour and delivery.




Nappi Code	Medicine Schedule	Medicine Proprietary Name	Active Ingredient	Strength	Dosage Form	Pack Size	Single Exit Price - ZAR (excl. VAT)	Single Exit Price - ZAR (incl. VAT)
3007613001	S5	Nalbain Injection 10mg/ml	Nalbuphine Hydrochloride	10	INJ	10	342.01	393.30
3007614001	S5	Nalbain Injection 20mg/ml	Nalbuphine Hydrochloride	20	INJ	5	342.01	393.30

WHY USE NALBAIN FOR YOUR PATIENTS?

- Fastest onset of action compared with competitors.¹
- Longest duration of action compared with competitors.¹
- Least potential for narcotic abuse compared with
- competitors.²
- Less withdrawal symptoms compared with competitors.³
- Similar **potency** to morphine.⁴
- Significantly less nausea and vomiting compared with competitors.⁴
- Nalbuphine has a good safety profile.⁴
- Nalbain offers the convenience of subcut, IM or IV routes of administration.⁵

Ultimately, it all comes down to what your patient needs - something you would know best.



Should you have any queries, please contact Aneesa Jacobs on **010 060 0741** or **admin@aryapharma.co.za**

Regards, Arya Pharma

Subcut: subcutaneous. IM: intramuscular. IV: intravenously.

References: 1. Jiang J. Xu. C, Zhang D, et al. Efficacy of Nalbuphine as a Local Anesthetic Adjuvant for Brachial Plexus Block: A Systematic Review and Meta-analysis. Pain Physician. 2022;25(9):E1339. 2. Conter F, Oliveira AR, Weston AC. Nalbuphine and addiction: From the basic science to clinical set. Journal of Clinical Research in Anesthesiology. 2019;2(2):1-5. 3. Kubica-Cielińska A, Czapla M, Juárez-Vela R, et al. Comparison of side effects of nalbuphine and morphine in the treatment of pain in children with cancer: a prospective study. Cancers. 2022 Jul;14(15):3617. 4. Zeng Z, Lu J, Shu C, et al. A comparision of nalbuphine information for and safety: meta-analysis of randomized controlled trials. Scientific reports. 2015 Jun;5(1):10927. 5. NALBAIN INJECTION 10 mg/ml and NALBAIN INJECTION 20 mg/ml Professional Information. Approved 20 September 2022.

Arya Pharma (PTY) Ltd. Reg. No.: K2015413329. Corner Barbara and North Reef Road, Elandsfontein, Germiston, 1401, Tel.: 010 060 0741. Email: admin@aryapharma.co.za Website: www.aryapharma.co.za